# Emergence of SARS-CoV-2 Omicron Variant JN.1 in Tamil Nadu, India - Clinical Characteristics and Novel Mutations

2 3 4

5

6

7

8 9

1

Sivaprakasam T. Selvavinayagam<sup>1†</sup>, Sathish Sankar<sup>2†</sup>, Yean K. Yong<sup>3,4†</sup>, Amudhan Murugesan<sup>5</sup>, Suvaiyarasan Suvaithenamudhan<sup>6†</sup>, Kannan Hemashree<sup>1</sup>, Manivannan Rajeshkumar<sup>1</sup>, Anandhazhvar Kumaresan<sup>1</sup>, Ramendra P. Pandey<sup>7</sup>, Saravanan Shanmugam<sup>8</sup>, Parthiban Arthydevi<sup>1</sup>, Masilamani S. Kumar<sup>1</sup>, Natarajan Gopalan<sup>9</sup>, Meganathan Kannan<sup>10</sup>, Narayanaiah Cheedarla<sup>11</sup>, Hong Y. Tan<sup>12</sup>, Ying Zhang<sup>13,4</sup>, Marie Larsson<sup>14</sup>, Pachamuthu Balakrishnan<sup>8</sup>, Vijayakumar Velu<sup>11</sup>, Siddappa N. Byrareddy<sup>15</sup>, Esaki M. Shankar<sup>16\*</sup>, and Sivadoss Raju<sup>1\*</sup>

10 11

12

- <sup>1</sup>State Public Health Laboratory, Directorate of Public Health and Preventive Medicine, DMS
- 13 Campus, Teynampet, Chennai 600 006, Tamil Nadu, India.
- <sup>14</sup> <sup>2</sup>Department of Microbiology, Centre for Infectious Diseases, Saveetha Dental College and
- 15 Hospitals, Saveetha Institute of Medical and Technical Sciences, Chennai 600 077, Tamil
- 16 Nadu, India.
- <sup>17</sup> <sup>3</sup>Laboratory Center, Xiamen University Malaysia, 43900 Sepang, Selangor, Malaysia.
- <sup>4</sup>Kelip□kelip! Center of Excellence for Light Enabling Technologies, Xiamen University
   Sepang, Selangor, Malaysia
- <sup>5</sup>Department of Microbiology, Government Theni Medical College and Hospital, Theni-625
   512, India.
- <sup>6</sup>School of Biomedical Sciences, Sri Balaji Vidyapeeth, (Deemed to be University),
   Pondicherry 607 402, India.
- <sup>7</sup>School of Health Sciences and Technology, UPES, Dehradun 248007, Uttarakhand, India.
- <sup>8</sup>Center for Infectious Diseases, Saveetha Medical College and Hospital, Saveetha Institute of
- 26 Medical and Technical Sciences, Saveetha University, Chennai 602105, Tamil Nadu, India.
- <sup>9</sup>Department of Epidemiology and Public Health, Central University of Tamil Nadu,
   Thiruvarur 610 005, India.
- <sup>10</sup>Blood and Vascular Biology, Department of Biotechnology, Central University of Tamil
   Nadu, Thiruvarur 610 005, India.
- <sup>31</sup> <sup>11</sup>Department of Pathology and Laboratory Medicine, Emory University School of Medicine,
- 32 Division of Microbiology and Immunology, Emory National Primate Research Center, Emory
- 33 Vaccine Center, Atlanta, GA, 30329, USA.
- <sup>12</sup>School of Traditional Chinese Medicine, Xiamen University Malaysia, Sepang, Selangor,
   Malaysia.
- <sup>13</sup>Chemical Engineering, Xiamen University Malaysia, Sepang, Malaysia.
- <sup>14</sup>Division of Molecular Medicine and Virology, Department of Biomedical and Clinical
   Sciences, Linköping University, 58 183 Linköping, Sweden.
- <sup>15</sup>Department of Pharmacology and Experimental Neuroscience, University of Nebraska
   Medical Center, Omaha, NE 68131, USA.
- <sup>16</sup>Infection and Inflammation, Department of Biotechnology, Central University of Tamil
   Nadu, Thiruvarur 610 005, India.
- 43
- <sup>†</sup>These authors contributed equally
- 45

# 46 **Corresponding authors**

- \*Sivadoss Raju, State Public Health Laboratory, Directorate of Public Health and Preventive
   Medicine, Teynampet, Chennai, India. Email: sivraju@gmail.com
- 49 **\*Esaki M Shankar**, Infection and Inflammation, Department of Biotechnology, Central
- 50 University of Tamil Nadu, Thiruvarur, India. Email: <u>shankarem@cutn.ac.in</u>
- 51

52 **Keywords:** Omicron variant, JN.1 variant, SARS-CoV-2, Whole genome sequencing, 53 mutation, Spike protein

54

56

55 **Running title:** Emergence of JN.1 SARS CoV-2 variant in Tamil Nadu.

#### 57 ABSTRACT

58 In December 2023, we observed a notable shift in the COVID-19 landscape, when the JN.1 59 emerged as a predominant SARS-CoV-2 variant with a 95% incidence. We characterized the 60 clinical profile, and genetic changes in JN.1, an emerging SARS-CoV-2 variant of interest. 61 Whole genome sequencing was performed on SARS-CoV-2 positive samples, followed by 62 sequence analysis. Mutations within the spike protein sequences were analyzed and compared 63 with the previous lineages and sublineages of SARS-CoV-2, to identify the potential impact of 64 these unique mutations on protein structure and possible functionality. Several unique and 65 dynamic mutations were identified herein. Our data provides key insights into the emergence of newer variants of SARS-CoV-2 in our region and highlights the need for robust and 66 sustained genomic surveillance of SARS-CoV-2. 67

68

#### 69 **INTRODUCTION**

The emergence of the novel coronavirus, SARS-CoV-2, in December 2019, has prompted an 70 71 urgent need to investigate the evolutionary dynamics of the virus, globally. Since their initial identification, these viruses have constantly undergone mutations, leading to the emergence of 72 73 several 'variants of concern' due to evolutionary dynamics [1]. Viral mutations inherent to the 74 replication process have led to the development of diverse variants characterized by distinct transmissibility and resistance profiles. Since the SARS-CoV-2 pandemic, the virus emerged 75 with five variants of concern (Alpha, Beta, Gamma, Delta, Omicron). Among these, the 76 77 Omicron variant (B.1.1.529) exhibited more than 50 characteristic mutations in different 78 motifs of the spike protein [2]. The virus along with its subsequent concerning sublineages and 79 variants, evolved with enhanced transmissibility, infectivity and immune evasion mechanism. 80 Notable subvariants, including BA.2, BA.5, and XBB were of particular interest due to their 81 rapid spread across the globe and evasion from neutralizing and monoclonal antibodies [3, 4]. 82 Specific genetic changes within the virus have conferred selective advantages, augmenting its ability to propagate and evade host immune responses, thereby presenting formidable 83 84 challenges to containment and treatment strategies [5].

85

86 These dynamic and ever-evolving viral mutations underscore the imperative necessity for 87 consistent monitoring and use of adaptive methodologies, such as whole-genome sequencing. 88 The ongoing surveillance of viral genomes facilitates the prompt identification of emerging 89 variants, playing a pivotal role in devising public health measures and targeted interventions. 90 Furthermore, a profound understanding of the genetic alterations steering the viral behaviour 91 becomes instrumental in developing effective treatments and vaccines, ensuring a resilient 92 response to the constantly evolving viral threats [6]. The impact of mutations on the protein 93 function is now studied through *in silico* methods [7, 8]. The difference in protein structures 94 induced by mutations resulting in different lineages during the viral evolutionary process [9]. 95 Here, we surveyed the population for SARS-CoV-2 Omicron subvariant JN.1 between 96 November and December 2023 as a part of the state's public health genomic surveillance 97 investigation, an ongoing programme of the Directorate of Public Health and Preventive 98 Medicine, Chennai, India since September 2021.

99

#### 100 MATERIALS AND METHODS

- 101
- 102 Study design

103 The study was part of the SARS-CoV-2 genomic surveillance by the State Public Health 104 Laboratory (SPHL), Directorate of Public Health and Preventive Medicine, Chennai, India. 105 COVID 19 diagnosis was based on clinical and laboratory tests using nasopharyngeal and 106 oropharyngeal swabs as per the guidelines of the Centers for Disease Control and Prevention 107 (CDC), Atlanta, USA. Written informed consent was obtained before sampling. Patients' 108 demographic details and clinical presentations were collected, including underlying 109 comorbidities, vaccination history, disease progression, and outcome. Of the 471 COVID-19-110 positive samples reported in Tamil Nadu between November and December 2023, 92 samples 111 with a cycle threshold (Ct) value of <25 were chosen for whole genome sequencing. RNA 112 extraction was carried out using MagMAX Viral/Pathogen II Nucleic Acid isolation kit 113 (Thermo Fisher Scientific, USA) and tested for SARS-CoV-2 using TaqPath COVID-19 RT-114 PCR kit (Thermo Fisher Scientific, USA) according to the manufacturer's instructions. The 115 RNA elutes were stored at -80°C until further testing.

116

#### 117 Ethics approval

The study was approved (EC No. 03092021) by the Institutional Ethics Committee of the
Madras Medical College and Hospital, Chennai. The clinical classification was based on the
Clinical Guidance for Management of Adult COVID□19 Patients by the Ministry of Health
and Family Welfare, Government of India (January 2022).

122

#### 123 Whole genome sequencing

124 Complementary DNA (cDNA) was prepared from RNA elutes using the SuperScript VILO 125 cDNA Synthesis kit (Invitrogen, Thermo Fisher Scientific, USA) as per the manufacturer's 126 instructions. Among 471 SARS-CoV-2 positive samples reported during the study period, 127 whole genome sequencing was carried out on 66 of 92 samples with cycle threshold (Ct) 128 values <25 as per the World Health Organization (WHO) criterion. Ion AmpliSeq library kit 129 (ThermoFisher Scientific, Waltham, USA) was used for the library preparation, and the final 130 library was adjusted to a final concentration of 75 pM using the low TE buffer and loaded onto 131 Ion Chef instrument for emulsion PCR, enrichment, and subsequent placement onto an Ion 540 132 chip. Next-generation sequencing (NGS) was conducted using the Ion Torrent NGS System 133 using the Ion GenStudio S5 Plus System (Thermo Fisher Scientific, Waltham, USA). Data analysis was performed using Torrent Suite<sup>TM</sup> software ver.5.18.1. The consensus sequence 134 135 was analysed using IRMA report ver.1.3.0.2. Annotation was performed using the SnpEff 136 program. The reads were aligned to the Wuhan Hu-1 strain as a reference genome (NCBI ID: 137 NC 045512.2).

138

#### 139 Phylogenetic and evolutionary analysis of spike protein

140 The phylogenetic analysis of SARS-CoV-2 was carried out to identify the mutations and 141 relatedness of the JN.1 variant with other SARS-CoV-2 variants using the Nextclade online 142 software v.3.2.0. (https://clades.nextstrain.org/) [10]. The nucleotide sequences coding for spike protein from the datasets available in the Nextclade as reference sequences and reference 143 144 genomes of SARS-CoV-2 variants from the NCBI database were selected and used to detect 145 the mutations. The Nextclade reference datasets, GenBank accession numbers and the list of 146 mutations are provided in **Supplementary Table 1**. The mutations that were unique to the 147 study sequences are called 'unique mutations', whereas those observed in the global JN.1 148 strains are called 'universal mutations'. The dynamic mutations characteristically appearing 149 and reappearing in the subsequent variants of SARS-CoV-2 are called 'dynamic mutations'. 150 Other mutations that were observed with no characteristic pattern were denoted as 'random 151 mutations'.

152

#### 153 Mutations and superimposition of 3D spike protein structure

154 Mutations unique to the study sequences were compared with the Wuhan Hu-1 and other 155 major lineages and sublineages, including XBB and the other reported JN.1 sequences. 156 Mutations were created in the 3D protein structure using PyMol Molecular Graphics System. 157 Using the mutagenesis function and best rotamer based on the frequency of its occurrence and clashes with neighbouring amino acids, the mutation was selected and created. A 3D structure 158 159 model was created with JN.1 specific mutations using Wuhan-Hu-1 as the reference (model 160 A), and a model with unique mutations was identified in our study using the reference JN.1 161 (model B). The above models were superimposed to identify any structural variations due to 162 these mutations. A 3D protein model for the Wuhan Hu-1 spike protein was built using Swissmodel protein structure homology modelling, upon which mutations were created using the 163 164 Pymol program. The quality of the developed model was analyzed using SAVES and 165 Procheck online server programs. The root mean square deviation (RMSD) values were used 166 to assess the mutation-induced structural effects on the protein, where a score of 0 indicates 167 identical structures and a high value indicates higher dissimilarity [11, 12].

168

# 169 **RESULTS**

#### 170 Clinico-demographic characteristics of the JN.1 cohort

The ongoing SARS-CoV-2 genomic surveillance activities at SPHL have identified the 171 172 dramatic emergence of the JN.1 variant of omicron by replacing the XBB variant between November and December 2023 (Fig 1A). The age of the JN.1 positive patients ranged from 1 173 174 to 89 years, with the median age during the study period being 51 (Fig 1B) and with an equal 175 proportion of male-to-female ratio (Fig 1C). More than 50% of the JN.1 patients had diabetes mellitus, followed by 21% of the cases with hypertension, and 10 % of the cases had both 176 177 diabetes mellitus and hypertension (Fig 1D). About 87% of the patients were presenting fever, 178 cold, cough and sore throat (Fig 1E & I). On analysing the vaccination status of the JN.1 179 positive patient, 93.5% had received COVID-19 vaccinations, indicating a high proportion of 180 vaccine breakthrough infections (Fig 1F). Among the vaccinated, 98% had received two or 181 more doses of COVID-19 vaccines (Fig 1G). About 45% of the JN.1 patients were 182 hospitalized, of which 20% had severe illnesses requiring oxygen support and ICU care with 183 ventilator support. However, no deaths were recorded (Fig 1H). Among the different 184 symptoms presented by the patients, fever was the most common presentation (69%) and was 185 predominant among the 10-20 years (86%) and 80-90 years (80%) of age. The other common 186 symptoms found were cough (55%) which was predominant in older age groups, rhinorrhea 187 (20%) in younger age groups and sore throat (predominant in 20-40 years (36%) and 60-80 188 years (32%) age groups. Breathlessness (6%) and myalgia (1.8%) were less prevalent and were 189 mostly seen in older age groups only (Fig 1I).

190

#### 191 Mutational analysis of spike protein

The S gene sequences of the 66 JN.1 study strains were analysed with different reference genomes and revealed several unique mutations in the different domains of the S protein including the receptor binding domain (RBD), signal peptide (SP) and N-terminal domain (NTD) (**Fig 2** and **Table 1**).

196

#### 197 Comparison of spike protein sequences of JN.1 with *Wuhan-Hu-1*

On comparing our JN.1 isolates with the reference sequence of the Wuhan-Hu-1 strain, we have identified 22 unique mutations and 3 dynamic mutations. Of the unique mutations, the majority of them occurred in NTD (n=16), followed by Heptad repeat (HR1/2) (n=3) and spike subdomain (SD) (n=2), whereas RBD showed one mutation (V503A). Among the dynamic mutations, two are seen in NTD (P85K and V90Y) and one in the signal domain (P681H). Also, JN.1 showed six universal mutations (three in NTD, two in RBD-N440K and N501Y and one in SD- D614G). This also encompasses some universal mutations, such as G142D,

which have been reported in several countries [13, 14]. Upon analysis of random mutations, we found that JN.1 variants showed 40 mutations across the spike protein when compared to *Wuhan-Hu-1* with a maximum number of mutations in RBD (23) followed by NTD (12) (**Table 2** and **Fig 2A**).

209

# 210 Comparison of spike protein sequences of JN.1 with BA.2

211 Similarly, the results from the comparison of JN.1 with the BA.2 variant show unique 212 mutations, including V83F, L84K, P85L, F86L, N87I, D88V, V90L, Y170E, Q218L, and 213 T307R and dynamic mutations such as P85L, V90Y in the NTD domain and the following 214 unique mutations T333R, F456L, Q506P, and P507T found within the RBD domain. There 215 was no occurrence of universal mutations within any of the domains. This shows the amino 216 acid change compared to BA.2 were identified individually (**Table 3** and **Fig 2B**). We also 217 found a total of 34 random mutations when comparing JN.1 and BA.2 with 10 mutations in 218 NTD and 18 in RBD. The fusion peptide (FP) domain showed a mutation – H681R.

219

#### 220 Comparison of spike protein sequences of JN.1 with XBB

Likewise, the comparison of JN.1 with the XBB variant showed no traces of universal 221 222 mutations and was found to have unique, dynamic, and random mutations. The unique 223 mutations in the NTD domain include A83V, L84K, P85K, F86L, N87I, D88V, V90L, F92V, 224 Y170E, and Q218L followed had two dynamic mutations (A83F and, V90Y). In the RBD 225 domain, unique mutations, including N331K, T333R, N334S, T346R, F456L, Q507P, and 226 P507T and dynamic mutation-T346I were identified. The other unique mutations, T315V, 227 S316C and F318I, were spotted in the intermediary region between NTD and RBD domains 228 (**Table 4** and Figure 2C). Our study shows 33 random mutations (13 in NTD, 14 in RBD, three 229 in SD1/2, two in HR1-2 and one in the FP).

230

#### 231 Evolutionary mutation patterns in spike protein sequences

Furthermore, the evolutionary relatedness of JN.1 is presented in a phylogenetic tree that depicts the hierarchy of the different lineages of the selected strain and the position of the JN.1 lineage in the tree. The JN.1 lineage showed an extended branch length in both rooted and unrooted trees (**Fig 3**).

236

#### 237 Mutational and conformational changes in spike protein

When our study sequences were compared with the reference genomes of different variants, 19 mutations were observed in our strains and previously reported JN.1 variants (but not seen in other lineages). This indicated that the mutations were unique to the JN.1 variant. The list of mutations and the specific motifs is given in **Table 5**, and the frequency of these mutations is given in **Supplementary Table 1**. The other 24 mutations that were observed in a few lineages/sub-lineages but not found in our 66 sequences were identified and listed in **Table 6**.

244

Intrigued by these mutations, we next elucidated the resulting protein structural changes with the reference protein sequences. The 19 JN.1-specific mutations were created in the model and superimposed with the reference protein. The superimposed structure showed an RMSD value of 0.071Å (**Fig 4A**). The 17 study-specific mutations were created and superimposed with the same model, which showed an RMSD value of 0.081Å (**Fig 4B**).

250

#### 251 **DISCUSSION**

Here, the study describes the detection of SARS-CoV-2 Omicron subvariant JN.1 during November and December-2023, as a part of the state public health genomic surveillance activity which has been happening since September 2021. In our recent study, we showed the mutational patterns of Omicron variants and the emergence of the XBB as a dominant variant

in January 2023 replacing BA.2 which continued till October 2023 [15, 16]. In September
2023, JN.1 was first identified in the United States [17] followingly many countries like
Canada, France, Singapore and the United Kingdom reported the emergence of JN.1 [18–21].
In India, the JN.1 variant was first identified on 6th October 2023. In Tamil Nadu, the first
case of JN.1 was reported on 27 December 2023, subsequently since then, JN.1 replaced the
XBB variant and was the most predominant SARS-CoV-2 variant in the state of Tamil Nadu,
India.

263

Along with the L455S, a hallmark FLip mutation of JN.1 in the spike protein, the present study identified mutations in different domains of the protein, particularly in the NTD, RBD, SD1/2 and HR1/2 domains. Furthermore, the study identified several mutations when compared to Wuhan-Hu-1, BA.2 and XBB. This indicates the adaptive evolutionary trends of the virus possibly due to reduced neutralizing antibody responses [22, 23].

269

270 Since the emergence of JN.1 in August 2023 as a descendant of the BA.2.86 lineage, it drew 271 much attention due to mutation-induced interference in viral binding to angiotensin-binding 272 enzyme (ACE2) receptors [24, 25]. A significant rise in numbers of JN.1 variant, post 273 vaccinations indicates breakthrough infections with enhanced capacity of immune evasion 274 [26]. The predecessor XBB variant had 82% of immune evasiveness among the vaccinated 275 individuals [15], whereas the current JN.1 variant by acquiring several mutations led to 276 structural changes in the spike protein, conferring 95% of immune evasiveness [27]. This 277 warranted a detailed investigation on other additional mutations that JN.1 harboured 278 subsequently from its predecessors [28]. The present study analyzed the mutational dynamics 279 of the virus it inherited across the lineages and sublineages. Though the study does not 280 represent the true prevalence of the JN.1 in India, the widespread distribution of this variant in 281 the community warrants nationwide genomic surveillance of SARS-CoV-2 under the 282 INSACOG network.

283

284 Although viruses are constantly known to evolve due to genetic diversity and evolutionary 285 selection pressure, the clinical and immunological outcomes are always unpredictable. It is 286 therefore important to carry out continuous surveillance on SARS-CoV-2 variants and their 287 mutational analysis [29]. The mutational pattern leads to virus evolution resulting in the 288 emergence of variants with enhanced transmissibility, severity and immune evasion [30]. The 289 disappearance and re-appearance of certain mutations (dynamic mutations), in the course of 290 virus evolution with any possible clinical relevance is generally overlooked in evolutionary 291 studies. The present study takes cognizance of such dynamic patterns during virus evolution. 292 The analysis revealed dynamic mutations such as P85L to P85K, V90L to V90Y in the NTD 293 domain and P681R to P681H in the intermediate region between SD1/2 and FP. These 294 dynamic mutations were identified by comparing JN.1 with the *Wuhan-Hu-1*, BA.2 and XBB. 295 The mutational spectrum in the NTD domain of the spike protein has been an important 296 mechanism in driving antigenic variation and host adaptation [31]. Studies indicate that potent 297 neutralizing antibodies to NTD interact with residues F140S, G142D, Y145D, K150E, W152R 298 and R158S [32]. The study also showed that antibodies against both RBD and NTD could 299 efficiently neutralize SARS-CoV-2, limiting the emergence of neutralization-escape mutants.

300

Our study indicated universal mutation-G142D and common mutations-Q146H and R158G identified in JN.1 variants in line with other studies [32, 33]. These findings further augment the emergence of vaccine-escape mutants. Similarly, by comparing the JN.1 with XBB, we show two dynamic mutations - A83V to A83F, V90L to V90Y in the NTD domain and T346R to T346I in the RBD domain. This indicates that these mutations would possibly contribute to the ongoing evolution of viral lineages, and their overall fitness and adaptability [34] Our

study identified a dynamic mutation P85K that has gradually evolved from the *Wuhan-Hu-1*and BA.2 strain and reshaped into a unique mutation in comparison with XBB [15]. This
indicates the genetic drift within the SARS-CoV-2 infection particularly in the JN.1 variant.
These results were further supported by the phylogenetic tree where the JN.1 lineage showed
an increased branch length demonstrating both the evolutionary divergence and its
relationships with the other lineages of SARS-CoV-2 [35].

313

314 The impact of unique mutations identified in the spike protein of the study strains on its 315 structure was analyzed by superimposing the mutant model with the wild-type model. The 316 structural alignment between the two models was analyzed with the equivalent backbone 317 atoms. Every single mutation causes concomitant changes in protein folding, conformation, 318 physiochemical properties and in situ function [36]. The conformational changes upon 319 superimposition are analyzed with RMSD as a measurement. The predicted structural 320 modifications on ab initio protein models are a known limitation on the robustness yet 321 considered to be the best approach for comprehensive analysis of variants [7]. Protein function 322 predictions are now studied increasingly through computational methods as the curated protein 323 structures, along with experimentally determined host-pathogen protein interactions [8]. In the 324 present study, as anticipated, the superimposed structure showed only a slight deviation 325  $(<0.1\text{\AA})$  compared to the reference strains. Nevertheless, these mutations may be the prelude 326 for further mutations in the course of the evolution of the new sub-lineage. Therefore, 327 monitoring the periodical changes in the virus dynamics is important [37]. Through the 328 combination of high-throughput sequencing technologies with phylogenetic analysis, it is 329 possible to assess parallel patterns of evolution driving significant phenotypic shifts. These 330 methods offer a framework to measure and predict future evolutionary occurrences [38].

331

332 The present study identified 19 unique mutations among the study sequences. The majority of 333 the mutations occurred in the NTD and RBD domains followed by the HR1/2 region. The 334 mutations and the following structural changes in the NTD have been implicated in reduced 335 epitope recognition ensuing immune viral escape. The mutations of the RBD domain have 336 been implicated significantly with infectability, transmissibility, and antibody resistance. Spike 337 proteins are known to accumulate multiple mutations upon evolution, subsequently ranking up 338 the virion spike density and infectivity. The present study identified novel mutations of the JN.1 variant, possibly contributing to high transmissibility and immune resistance. In addition, 339 340 the structural conformation analysis by superimposing them with reference protein structure 341 indicated structural divergence. The considerable deviations measured in conventional RMSD 342 could have been studied further to elucidate its functional variability. Our study also identified 343 24 mutations that were present in previous lineages but lost in the JN.1 variant, indicating the 344 dynamicity of such mutations. These dynamic mutations might play a substantial role in the 345 viral evolution and pathogenicity mechanism and are to be studied.

346

#### 347 CONCLUSIONS

Recognizing the significance of mutations is crucial for modifying public health strategies and therapeutic interventions. This study aimed to characterize the clinical profiling and genetic modifications of the JN.1 variant to the previous variants of SARS-CoV-2, including the wild type *Wuhan-Hu-1*, BA.2, and XBB. The study showed that the prevalent mutations in JN.1 may be responsible for their immune evasive properties, and acknowledged that the genetic landscape of SARS-CoV-2 is inconstant and this capability to identify and respond to alterations in the genetic composition of the virus is vital for effective pandemic governance.

355

#### 356 Author contributions

357 Sivaprakasam T. Selvavinayagam, Masilamani Senthilkumar, Yean K. Yong, Suvaiyarasan 358 Suvaithenamudhan, Amudhan Murugesan, Marie Larsson, Pachamuthu Balakrishnan, 359 Siddappa N. Byrareddy, Vijayakumar Velu, Esaki M. Shankar, and Sivadoss Raju designed 360 the study and were responsible for conceptualization and data curation. Sivaprakasam T. 361 Selvavinayagam, Narayanaiah Cheedarla, Kannan Hemashree, Sathish Sankar, Yean K. Yong, 362 Hong Y. Tan, Ying Zhang, Parthiban Arthydevi, Ramendra P. Pandey, Manivannan 363 Rajeshkumar, Anandhazhvar Kumaresan, Natarajan Gopalan, Meganathan Kannan, Marie 364 Larsson, Saravanan Shanmugam, Vijayakumar Velu, Pachamuthu Balakrishnan, Esaki 365 M.Shankar, and Sivadoss Raju conducted the analysis, and were responsible for methodology, 366 formal analysis, validation, and visualization. Sivaprakasam T. Selvavinayagam, Yean K. 367 Yong, Marie Larsson, Vijayakumar Velu, Esaki M. Shankar, and Sivadoss Raju wrote the first 368 draft of the manuscript. All authors provided critical inputs and approved the final version of 369 the manuscript for publication.

370

# 371 Conflicts of interest

There are no conflicts of interest to disclose by any authors.

373

# 374 **Funding information**

375 are funded by the National Health Mission, S.T.S. and S.R. Tamil Nadu 376 (680/NGS/NHMTNMSC/ENGG/2021) for the Directorate of Public Health and Preventive 377 Medicine, WGS facility. M.L. is supported by grants through AI52731, the Swedish Research 378 Council, the Swedish, Physicians against AIDS Research Foundation, the Swedish 379 International Development Cooperation Agency, SIDASARC, VINNMER for Vinnova, 380 Linköping University Hospital Research Fund, CALF, and the Swedish Society of Medicine. 381 V.V. is supported by the Office of Research Infrastructure Programs (ORIP/NIH) base grant 382 P51 OD011132 to ENPRC. A.M. is supported by Grant No. 12020/04/2018 □ HR, Department 383 of Health Research, Government of India. The funders of the study had no role in the study 384 design, data collection, data analysis, data interpretation, or writing of the report. The authors thank the Indian SARS CoV 2 Genomics Consortium (INSACOG), Department of 385 386 Biotechnology, Ministry of Science and Technology, Government of India for their approval 387 and inclusion of the State Public Health Laboratory (SPHL) as INSAGOG Genomic Sequencing Laboratory (IGSL) vide File No: RAD 22017/28/2020 KGDDBT Part (6) 388 389 Dated 29th December 2021.

390

# 391 Ethical approval statement

The study was approved by the Institutional Ethical Committee of Madras Medical College and Hospital, Chennai (EC No. 03092021).

# 394

# 395 **Patient consent statement**

396 Patient written informed consent was obtained.

397

# 398 Acknowledgements

399 and S.R. are funded by the S.T.S. National Health Mission, Tamil Nadu 400 (680/NGS/NHMTNMSC/ENGG/2021) for the Directorate of Public Health and Preventive 401 Medicine, WGS facility. M.L. is supported by grants through AI52731, the Swedish Research, 402 the Swedish Physicians against AIDS Research Foundation, the Swedish International 403 Development Cooperation Agency, SIDASARC, VINNMER for Vinnova, Linköping 404 University Research Fund, CALF, and the Swedish Society of Medicine. V.V. is supported by 405 the Office of Research Infrastructure Programs(ORIP/NIH) base grant P51 OD011132 to 406 ENPRC. A.M. is supported by Grant No. 12020/04/2018 HR, Department of Health 407 Research, Government of India. The funders of this study had no role in the study design, data

collection, data analysis, data interpretation, or writing of the report. The authors thank the
Indian SARS CoV 2 Genomic Consortium (INSACOG), Department of Biotechnology,
Ministry of Science and Technology, Government of India for their approval and inclusion of
the State Public Health Laboratory (SPHL) as INSAGOG Genomic Sequencing Laboratory
(IGSL) vide File No: RAD 22017/28/2020 KGDDBT Part (6) Dated 29th December 2021.

413

# 414 Data Availability Statement

The data that support the findings of this study are available from the corresponding author upon reasonable request. The identified clinical data of patients in the study and the 'in-house'

- bioinformatics pipeline in Python are available on request to the corresponding authors.
- 418

# 419 Abbreviations

ACE2, angiotensin converting enzyme-2; CDC, Centers for Disease Control and Prevention; 420 421 cDNA, complementary DNA; COVID 19, coronavirus disease 2019; Ct, cycle threshold 422 value; FP, fusion peptide; HDU, high dependency unit; HR, heptad repeat; ICU, intensive care 423 unit; Polymerase Chain Reaction; NGS, next generation sequencing; NTD, N terminal 424 domain; QC, quality control; RBD, receptor binding domain; RMSD, root mean square 425 deviation; RT-PCR, Reverse transcription PCR; SARS-CoV-2, Severe Acute Respiratory 426 Syndrome Coronavirus 2; SD, spike subdomain; SP: signal peptide; SPHL, State Public Health 427 Laboratory; TE, Tris-EDTA; TM: Transmembrane domain; VOC, variants of concern; WGS, 428 whole genome sequencing.

429

# 430 **References**

- 4311.Zaidi AK, Singh RB. SARS-CoV-2 variant biology and immune evasion. Prog Mol Biol Transl Sci4322024;202:45-66.
- 4332.Fan Y, Li X, Zhang L, Wan S, Zhang L, et al. SARS-CoV-2 Omicron variant: recent progress and434future perspectives. Signal Transduction and Targeted Therapy 2022 7:1 2022;7:1–11.
- 4353.Chakraborty C, Bhattacharya M, Chopra H, Islam MA, Saikumar G, et al. The SARS-CoV-2436Omicron recombinant subvariants XBB, XBB.1, and XBB.1.5 are expanding rapidly with unique437mutations, antibody evasion, and immune escape properties an alarming global threat of a438surge in COVID-19 cases again? Int J Surg 2023;109:1041.
- 4. Selvavinayagam ST, Yong YK, Joseph N, Hemashree K, Tan HY, et al. Low SARS-CoV-2 viral
  440 load among vaccinated individuals infected with Delta B.1.617.2 and Omicron BA.1.1.529 but
  441 not with Omicron BA.1.1 and BA.2 variants. Front Public Health 2022;10:1018399.
- Mahilkar S, Agrawal S, Chaudhary S, Parikh S, Sonkar SC, *et al.* SARS-CoV-2 variants: Impact
  on biological and clinical outcome. *Front Med (Lausanne)*;9. Epub ahead of print 10 November
  2022. DOI: 10.3389/FMED.2022.995960.
- Kumari M, Lu RM, Li MC, Huang JL, Hsu FF, *et al.* A critical overview of current progress for
  COVID-19: development of vaccines, antiviral drugs, and therapeutic antibodies. *J Biomed Sci*;29. Epub ahead of print 1 December 2022. DOI: 10.1186/S12929-022-00852-9.
- 4487.Lee D, Redfern O, Orengo C. Predicting protein function from sequence and structure. Nat Rev449Mol Cell Biol 2007;8:995–1005.
- 450 8. Pál C, Papp B, Lercher MJ. An integrated view of protein evolution. *Nat Rev Genet* 2006;7:337–
  451 348.

- 452 9. **Lomoio U, Puccio B, Tradigo G, Guzzi PH, Veltri P**. SARS-CoV-2 protein structure and sequence 453 mutations: Evolutionary analysis and effects on virus variants. *PLoS One* 2023;18:e0283400.
- 45410.Aksamentov I, Roemer C, Hodcroft E, Neher R. Nextclade: clade assignment, mutation calling455and quality control for viral genomes. J Open Source Softw 2021;6:3773.
- 456 11. Ravantti JJ, Martinez-Castillo A, Abrescia NGA. Superimposition of Viral Protein Structures: A
  457 Means to Decipher the Phylogenies of Viruses. *Viruses*;12. Epub ahead of print 1 October 2020.
  458 DOI: 10.3390/V12101146.
- 459 12. Carugo O, Pongor S. A normalized root-mean-spuare distance for comparing protein three 460 dimensional structures. *Protein Sci* 2001;10:1470.
- 13. Davis JJ, Long SW, Christensen PA, Olsen RJ, Olson R, et al. Analysis of the ARTIC Version 3
  and Version 4 SARS-CoV-2 Primers and Their Impact on the Detection of the G142D Amino Acid
  Substitution in the Spike Protein. *Microbiol Spectr*;9. Epub ahead of print 22 December 2021.
  DOI: 10.1128/SPECTRUM.01803-21.
- 465 14. Singh P, Sharma K, Singh P, Bhargava A, Negi SS, et al. Genomic characterization unravelling
  466 the causative role of SARS-CoV-2 Delta variant of lineage B.1.617.2 in 2nd wave of COVID-19
  467 pandemic in Chhattisgarh, India. *Microb Pathog*;164. Epub ahead of print 1 March 2022. DOI:
  468 10.1016/J.MICPATH.2022.105404.
- Selvavinayagam ST, Karishma SJ, Hemashree K, Yong YK, Suvaithenamudhan S, et al. Clinical
  characteristics and novel mutations of omicron subvariant XBB in Tamil Nadu, India a cohort
  study. The Lancet regional health Southeast Asia;19. Epub ahead of print 1 December 2023.
  DOI: 10.1016/J.LANSEA.2023.100272.
- 473 16. Selvavinayagam ST, Suvaithenamudhan S, Yong YK, Hemashree K, Rajeshkumar M, et al.
  474 Genomic surveillance of omicron B.1.1.529 SARS-CoV-2 and its variants between December
  475 2021 and March 2023 in Tamil Nadu, India—A state-wide prospective longitudinal study. J Med
  476 Virol 2024;96:e29456.
- 477 17. Looi MK. Covid-19: WHO adds JN.1 as new variant of interest. *BMJ* 2023;383:p2975.
- Planas D, Staropoli I, Michel V, Lemoine F, Donati F, et al. Distinct evolution of SARS-CoV-2
  Omicron XBB and BA.2.86/JN.1 lineages combining increased fitness and antibody evasion. Nat *Commun*;15. Epub ahead of print 1 December 2024. DOI: 10.1038/S41467-024-46490-7.
- Wannigama DL, Amarasiri M, Phattharapornjaroen P, Hurst C, Modchang C, et al.
  Wastewater-based epidemiological surveillance of SARS-CoV-2 new variants BA.2.86 and
  offspring JN.1 in south and Southeast Asia. J Travel Med. Epub ahead of print 4 March 2024.
  DOI: 10.1093/JTM/TAAE040.
- 485 20. Ou G, Yang Y, Zhang S, Niu S, Cai Q, *et al.* Evolving immune evasion and transmissibility of
  486 SARS-CoV-2: The emergence of JN.1 variant and its global impact. *Drug Discov Ther*;18. Epub
  487 ahead of print 29 February 2024. DOI: 10.5582/DDT.2024.01008.
- 488 21. Kaku Y, Okumura K, Padilla-Blanco M, Kosugi Y, Uriu K, *et al.* Virological characteristics of the
   489 SARS-CoV-2 JN.1 variant. *Lancet Infect Dis* 2024;24:e82.
- Wang Q, Iketani S, Li Z, Liu L, Guo Y, *et al.* Alarming antibody evasion properties of rising
  SARS-CoV-2 BQ and XBB subvariants. *Cell* 2023;186:279-286.e278.

- Patel N, Trost JF, Guebre-Xabier M, Zhou H, Norton J, et al. XBB.1.5 spike protein COVID-19
  vaccine induces broadly neutralizing and cellular immune responses against EG.5.1 and
  emerging XBB variants. Scientific Reports 2023 13:1 2023;13:1–11.
- 49524.Kaku Y, Okumura K, Padilla-Blanco M, Kosugi Y, Uriu K, et al. Virological characteristics of the496SARS-CoV-2 JN.1 variant. Lancet Infect Dis 2024;24:e82.
- 49725.Uriu K, Ito J, Kosugi Y, Tanaka YL, Mugita Y, et al.Transmissibility, infectivity, and immune498evasion of the SARS-CoV-2 BA.2.86 variant. Lancet Infect Dis 2023;23:e460–e461.
- 499 26. Yang S, Yu Y, Xu Y, Jian F, Song W, *et al.* Fast evolution of SARS-CoV-2 BA.2.86 to JN.1 under
  500 heavy immune pressure. *Lancet Infect Dis* 2024;24:e70–e72.
- Karyakarte RP, Das R, Rajmane M V, Dudhate S, Agarasen J, *et al.* Appearance and Prevalence
   of JN.1 SARS-CoV-2 Variant in India and Its Clinical Profile in the State of Maharashtra. *Cureus*.
   Epub ahead of print 22 March 2024. DOI: 10.7759/cureus.56718.
- 504 28. Kosugi Y, Plianchaisuk A, Putri O, Uriu K, Kaku Y, *et al.* Characteristics of the SARS-CoV-2
  505 omicron HK.3 variant harbouring the FLip substitution. *Lancet Microbe*;0. Epub ahead of print
  506 January 2024. DOI: 10.1016/s2666-5247(23)00373-7.
- 50729.Singh J, Pandit P, McArthur AG, Banerjee A, Mossman K. Evolutionary trajectory of SARS-CoV-5082 and emerging variants. Virology Journal 2021 18:1 2021;18:1-21.
- 30. Goga A, Bekker LG, Garrett N, Reddy T, Yende-Zuma N, et al. Breakthrough SARS-CoV-2
   infections during periods of delta and omicron predominance, South Africa. *The Lancet* 2022;400:269–271.
- 51231.Cantoni D, Murray MJ, Kalemera MD, Dicken SJ, Stejskal L, et al. Evolutionary remodelling of513N-terminal domain loops fine-tunes SARS-CoV -2 spike . EMBO Rep;23. Epub ahead of print 6514October 2022. DOI: 10.15252/EMBR.202154322/SUPPL\_FILE/EMBR202154322-SUP-0002-515DATASETEV1.XLSX.
- Haslwanter D, Dieterle ME, Wec AZ, O'brien CM, Sakharkar M, et al. A Combination of
  Receptor-Binding Domain and N-Terminal Domain Neutralizing Antibodies Limits the
  Generation of SARS-CoV-2 Spike Neutralization-Escape Mutants. *mBio*;12. Epub ahead of print
  1 October 2021. DOI: 10.1128/MBIO.02473-21.
- Suryadevara N, Shrihari S, Gilchuk P, VanBlargan LA, Binshtein E, *et al.* Neutralizing and
   protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV 2 spike protein. *Cell* 2021;184:2316-2331.e15.
- 52334.Harvey WT, Carabelli AM, Jackson B, Gupta RK, Thomson EC, et al. SARS-CoV-2 variants, spike524mutations and immune escape. Nat Rev Microbiol 2021;19:409–424.
- 52535.Negi SS, Schein CH, Braun W. Regional and temporal coordinated mutation patterns in SARS-526CoV-2 spike protein revealed by a clustering and network analysis. Sci Rep;12. Epub ahead of527print 1 December 2022. DOI: 10.1038/S41598-022-04950-4.
- 36. Ravantti JJ, Martinez-Castillo A, Abrescia NGA. Superimposition of Viral Protein Structures: A
  Means to Decipher the Phylogenies of Viruses. *Viruses*;12. Epub ahead of print 1 October 2020.
  DOI: 10.3390/V12101146.

- 531 37. Bloom JD, Beichman AC, Neher RA, Harris K. Evolution of the SARS-CoV-2 Mutational
- 532 Spectrum. *Mol Biol Evol*;40. Epub ahead of print 4 April 2023. DOI:
- 533 10.1093/MOLBEV/MSAD085.
- 534 38. Dolan PT, Whitfield ZJ, Andino R. Mapping the Evolutionary Potential of RNA Viruses. Cell Host
   535 Microbe 2018;23:435–446.

536





FIGURE 1 A) Analysis of the proportions of different SARS-CoV-2 variants circulating in 541 Tamil Nadu over time. The x-axis represents the timeline, the y-axis represents the proportion, 542 and different colors represent distinct variants. **B**—**H**) Clinico-demographic characteristics, 543 where **B**) median age, **C**) gender, **D**) symptoms, **E**) comorbidity, **F**) vaccination status, **G**) 544 number of doses received, H) medical support, and I) Common symptoms among different age 545 546 groups. Note: All patients recovered from COVID-19. 547



548

**FIGURE 2** Amino acid changes in the different domains of JN.1 in comparison with *Wuhan-Hu-1*, BA.2, and XBB (Red colour indicates the unique mutations, the blue colour indicates the dynamic mutations, the black colour indicates random mutations and pale red indicates universal mutations). Fusion peptide (FP), Heptad Repeat (HR1/2), N-terminal domain (NTD), Receptor Binding Domain (RBD), Signal peptide (SP), Spike Subdomain (SD) and Transmembrane domain (TM) are the different motifs of the spike glycoprotein.



FIGURE 3 The phylogenetic analysis of the JN.1 variant using a rooted tree and an unrooted tree illustrates the evolutionary relatedness among the sequences of JN.1 (n=66) compared with the reference genome of SARS-CoV-2 (*Wuhan-Hu-1*).



565

FIGURE 4 Superimposition of protein models. A: Superimposed protein model of *Wuhan Hu-1* reference model (red) with JN.1 specific mutations (blue). B: Superimposed protein
 model of JN.1 variant (green) with the study-specific unique mutation model identified in our
 study patients (red).

570

571

# Table 1: Unique and dynamic mutational pattern in spike protein among different lineages.

S.No	Comparison	Unique Mutations (n)	Unique Mutations	Dynamic Mutations (n)	Dynamic Mutations
1	JN.1 variants with Wuhan-Hu-1	22	T20L, P26Q, D53E, F55L, S60F, N81S, V83F, L84K, P85L, F86L, N871, D88V, V90L, P174S,Q218L, A288S, V503A, P681R, M740I, S939F, V1104L, P1162L	3	P85K, V90Y, P681R
2	JN.1 variants with BA.2	14	V83F, L84K, P85L, F86L, N87I, D88V, V90L, Y170E, Q218L, T307Q, T333R, F456L, Q506P, P507T	2	P85L, V90Y
3	JN.1 variants with XBB	20	A83V, L84K, P85K, F86L, N87I, D88V, V90L, F92V, Y170E, Q218L, T315V, S316C, F318I, N331K, T333R, N334S, T346R, F456L, Q506P, P507T	3	A83F,V90Y,T34 6I

578	Table 2: Unique, dynamic, universal, and random mutations in the spike protein of JN.1 compared to the Wuhan-Hu-1 sequence.
579	

U	UNIQUE MUTATION			DYNAMIC MUTATION			UNIVERSAL MUTATION			<b>RANDOM MUTATION</b>				
NTD	RBD	SD	HR1/HR2	NTD	RBD	SD	NTD	RBD	SD	NTD	RBD	SD	FP	HR1/HR2
V83F	V503A	P681R	S939F	P85K	-	P681H	G142D	N440K	D614G	T19I	G339H	N764K	D796Y	Q954H
L84K	-	M740I	V1104L	V90Y	-	-	T307Q	S477N	-	R21T	K356T	-	-	N969K
P85L	-	-	P1162L	-	-	-	-	N501Y	-	A27S	S371F	-	-	P1143L
F86L	-	-	-	-	-	-	-	-	-	S50L	S373P	-	-	-
N87I	-	-	-	-	-	-	-	-	-	V127F	S375F	-	-	-
D88V	-	-	-	-	-	-	-	-	-	F157S	T376A	-	-	-
V90L	-	-	-	-	-	-	-	-	-	R158G	R403K	-	-	-
Q218L	-	-	-	-	-	-	-	-	-	L212I	D405N	-	-	-
T20L	-	-	-	-	-	-	-	-	-	V213G	R408S	-	-	-
P26Q	-	-	-	-	-	-	-	-	-	L216F	K417N	-	-	-
D53E	-	-	-	-	-	-	-	-	-	H245N	V445H	-	-	-
F55L	-	-	-	-	-	-	-	-	-	A264D	G446S	-	-	-
S60F	-	-	-	-	-	-	-	-	-	-	N450D	-	-	-
N81S	-	-	-	-	-	-	-	-	-	-	L452W	-	-	-
P174S	-	-	-	-	-	-	-	-	-	-	L455S	-	-	-
A288S	-	-	-	-	-	-	-	-	-	-	N460K	-	-	-
-	-	-	-	-	-	-	-	-	-	-	T478K	-	-	-
-	-	-	-	-	-	-	-	-	-	-	N481K	-	-	-
-	-	-	-	-	-	-	-	-	-	-	E484K	-	-	-
-	-	-	-	-	-	-	-	-	-	-	F486P	-	-	-
-	-	-	-	-	-	-	-	-	-	-	Q498R	-	-	-
-	-	-	-	-	-	-	-	-	-	-	Y505H	-	-	-

581 Table 3: Unique, dynamic, universal, and random mutations in the spike protein of JN.1 compared to the BA.2 sequence.

U	NIQUE M	IUTA	TION	DYNAMI	IC MUTATI	ON	UN MU	IVERSAL JTATION	_ [	RANDOM MUTATION			I	
NTD	RBD	SD	HR1/HR2	NTD	RBD	SD	NTD	RBD	SD	NTD	RBD	SD	FP	HR1/HR2
V83F	T33R	-	-	P85K	-	-	-	-	-	R21T	I332V	E554K	H681R	S939F
L84K	F456L	-	-	V90Y	-	-	-	-	-	A27S	G339H	A570V	-	P1143L
P85L	Q506P	-	-	-	-	-	-	-	-	S50L	R346T	P621S	-	
F86L	P507T	-	-	-	-	-	-	-	-	V127F	K356T	-	-	-
N87I	-	-	-	-	-	-	-	-	-	F157S	S375F	-	-	-
D88V	-	-	-	-	-	-	-	-	-	R158G	T376A	-	-	-
V90L	-	-	-	-	-	-	-	-	-	L212I	R403K	-	-	-
Q218L	-	-	-	-	-	-	-	-	-	L216F	V445H	-	-	-
Y170E	-	-	-	-	-	-	-	-	-	H245N	G446S	-	-	-
T307Q	-	-	-	-	-	-	-	-	-	A264D	N450D	-	-	-
-	-	-	-	-	-	-	-	-	-	-	L452W	-	-	-
-	-	-	-	-	-	-	-	-	-	-	L455W	-	-	-
-	-	-	-	-	-	-	-	-	-	-	N460K	-	-	-
-	-	-	-	-	-	-	-	-	-	-	N481K	-	-	-
-	-	-	-	-	-	-	-	-	-	-	A484K	-	-	-
-	-	-	-	-	-	-	-	-	-	-	F486P	-	-	-
-	-	-	-	-	-	-	-	-	-	-	R493Q	-	-	-
-	-	-	-	-	-	-	-	-	-	-	H505Y	-	-	-

medRxiv preprint doi: https://doi.org/10.1101/2024.04.16.24305882; this version posted April 19, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

UN	UNIQUE MUTATION				IC MUTAT	UNIVERSAL MUTATION			RANDOM MUTATION					
NTD	RBD	SD	HR1/HR2	NTD	RBD	SD	NTD	RBD	SD	NTD	RBD	SD	FP	HR1/HR2
A83V	N331K	-	-	A83F	T346I	-	-	-	-	R21T	I332V	E554K	H681R	S939F
L84K	T333R	-	-	V90Y	-	-	-	-	-	A27S	K356T	A570V	-	P1143L
P85K	N334S	-	-	-	-	-	-	-	-	S50L	I368L	P621S	-	-
F86L	T346R	-	-	-	-	-	-	-	-	V127F	R403K	-	-	-
N87I	F456L	-	-	-	-	-	-	-	-	Q146H	P445H	-	-	-
D88V	Q506P	-	-	-	-	-	-	-	-	F157S	N450D	-	-	-
V90L	P507T	-	-	-	-	-	-	-	-	R158G	L452W	-	-	-
F92V	-	-	-	-	-	-	-	-	-	E183Q	L455W	-	-	-
Y170E	-	-	-	-	-	-	-	-	-	L212I	N460K	-	-	-
Q218L	-	-	-	-	-	-	-	-	-	E213G	N481K	-	-	-
T315V	-	-	-	-	-	-	-	-	-	L216F	A484K	-	-	-
S316C	-	-	-	-	-	-	-	-	-	H245N	S486P	-	-	-
F318I	-	-	-	-	-	-	-	-	-	A264D	S490F	-	-	-
-	-	-	-	-	-	-	-	-	-	-	H505Y	-	-	-

Table 4: Unique, dynamic, universal, and random mutations in the spike protein of JN.1 compared to the XBB sequence.

S. no	Mutations	Motif	Subunit
1	R21T	NTD	
2	S50L	NTD	
3	V127F	NTD	
4	F157S	NTD	
5	R158G	NTD	
6	L216F	NTD	
7	H245N	NTD	
8	A270D	NTD	
9	I332V	RBD	S1
10	K356T	RBD	
11	R403K	RBD	
12	N450D	RBD	
13	L455S	RBD	
14	N481K	RBD	
15	E554K	SD1/2	
16	A570V	SD1/2	
17	P621S	SD1/2	
18	S939F	HR1	S2
19	P1143L	HR2	

Table 5: List of mutations observed in our strains and previously reported JN.1 variants.

S. No	Mutations	Motif	Variants bearing the mutation
1.	L24S	NTD	BA.2; BA.2.75; BA.2.10; BA.4; BA.5
2.	A67V	NTD	BA.1
3.	H146Q	NTD	XBB.1
4.	K147E	NTD	BA.2.75
5.	W152R	NTD	BA.2.75
6.	F157L	NTD	BA.2.75
7.	Q183E	NTD	XBB1
8.	I210V	NTD	BA.2.75
9.	L212V	NTD	BA.1
10.	R214K	NTD	BA.1
11.	G252V	NTD	BA.1
12.	G257S	NTD	BA.2.75
13.	L368I	RBD	XBB1
14.	Y449S	RBD	BA.1
15.	F490L	RBD	BA.1
16.	Q493R	RBD	BA.2;BA.1.1.529;BA2.10
17.	G496N	RBD	BA.1
18.	T500A	RBD	BA.1
19.	G502S	RBD	XBB1
20.	N658S	SD1/2	BA.4
21.	Q755R	SD1/2-FP	BA.2.75
22.	D950N	HR1	BA.1.617.2
23.	L981F	HR1	BA.1
24.	S982A	HR1	BA.1.1
25.	V1228L	TM	BA.1

Table 6: List of mutations observed in a few lineages/sub-lineages but not in our study.



F. Vaccination status



G. No. of vaccine dose



H. Medical support



Common symptoms among different age groups



A Cor	nparison c	of JN.1 var	riant wit	h Wuha
S	31 Subunit	5		S2 Su
	. •	Spike Gly	coprotei	n
	/ ~		< <u></u>	
SP NTD	RBD	SD 1/2	<b>F</b> P	HR1
1 13 14 305 319	) 54	1 680	788 806	91 <mark>2 98</mark> 4
T19I V127F T307Q T20L G142D R21T F157S P26Q R158G A27S P174S S50L L212I D53E V213G F55L L216F S60F Q218L N81S H245N V83F A264D L84K A288S P85L P85K F86L N87I	I332V G446S G339H N450D K356T L452W S371F L455S S373P N460K S375F S477N T376A T478K R403K N481K D405N E484K R408S F486P K417N Q498R N440K N501Y V445H V503A Y505H	E554K P68 A570V P68 D614G M74 P621S N76 H655Y N679K	1R D796Y 1H 40I 34K	S939F V: Q954H P1 N969K G142 T20L P26Q D58E F55L S60F Q218L
D88V V90L V90Y				P681 P681

P681H

C

medRxiv preprint doi: https://doi.org/10.1101/2024.04.16.24305882; this version posted April 19, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

	S1 Subuni	t		S2 Subunit	
		Spike G	lycoprote	ein	
SP NTD	RBD	SD 1/2	FP	HR1 HR2	Γ
13 14 305	<b>319</b> 54	41 680	788 806	912 984 1163 12	13
R21T V90Y T3 A27S F92V S3 S50L V127F F3 A83V Q146H A83F F157S L84K R158G P85K Y170E F86L E183Q N87I L212I D88V E213G V90L L216F Q218L H245N A264D	<ul> <li>815V N331K L452W</li> <li>816C I332V L455W</li> <li>818I T333R F456L</li> <li>N334S N460K</li> <li>T346R N481K</li> <li>T346I A484K</li> <li>K356T S486P</li> <li>I368L S490F</li> <li>R403K H505Y</li> <li>P445H Q506P</li> <li>N450D P507T</li> </ul>	E554K A570V P621S	H681R	S939F P1143L	A83V A83F F8 D8 F9



# Comparison of JN.1 variant with XBB





